Prof. Thomas C. Baghai



Academic Degree(s)





Current Position


  • Director Medical Services, Medical Institutions District Oberpfalz
  • Professorship for Clinical Neurosciences, University Regensburg


Professional Experience


  • Supervising assistant medical director, Dept. for Psychiatry and Psychotherapy,Universiy Regensburg (2010-2016)
  • Assistant medical director, Dept. for Psychiatry and Psychotherapy, Ludwig-Maximilian-University of Munich (2006-2011)
  • Board certification in Psychiatry and Psychotherapy (2001)


Education & Training

  • Residency training at the Psychiatric Hospital of the Ludwig-Maximilians-University Munich (1991-2001)




  • ECNP Poster Award (13th ECNP Congress Munich) (2000)
  • AGNP-Preis für Forschung in der Psychopharmakologie der Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (2005)
  • Kraepelin/Alzheimer Medaille der Klinik für Psychiatrie und Psychotherapie der LMU München (2011)


Research Grants


  • 2015 Bundesministerium für Bildung und Forschung (BMBF) OptiMD (Novel strategies for the optimized treatment of depression), Subprojekt 3 (Relevance of microbiome composition for subtypes of depression, response and side effects during antidepressant treatment)
  • 2004 Deutsche Forschungsgemeinschaft – Comorbidity Depression - cardiovascular disorders: polymorphisms of the ACE- and Gb3-gene, inflammation biomarkers and intima-media-thickness in patients suffering from depression and/or coronary heart disease
  • 2002 Friedrich Bauer Foundation Grant for investigations in the impact of the Insertion/Deletion polymorphism in the Angiotensin I-converting enzyme on hypothalamic-pituitary-adrenocortical-axis dysregulation in major depressed patients (No. FBI 0046/2002)
  • 2000 Friedrich Bauer Foundation Grant for salivary based investigations in hypothalamic-pituitary-adrenocortical-axis dysfuncition in depression (No. FBI 0051/2000)​


Committee & Membership


  • World Psychiatric Association (WPA), Section on Pharmacopsychiatry
  • Collegium Internationale Neuro-Psychopharmacologicum (CINP), CINP Antidepressant Task-Force
  • World Federation of Societies of Biological Psychiatry (WFSBP); WFSBP Task-Force on ECT
  • European College of Neuropsychopharmacology (ECNP)


Selected Publication


  • Baghai, T.C., Varallo-Bedarida, G., Born, C., Häfner, Schüle, C., S., Eser, D., Länger, A., Zill, P., von Schacky, C., Rupprecht, R., Bondy, B. 2012 Classical risk factors and inflammatory biomarkers as a biological link between cardiovascular disease and major depression. Int J Mol Sci. 2018 Jun 12: 19(6).
  • Lima-Ojeda, J.M., Rupprecht, R., Baghai, T.C. "I Am I and My Bacterial Circumstances": Linking Gut Microbiome, Neurodevelopment, and Depression. Front Psychiatry. 2017 Aug 22: 8:153.
  • Lima-Ojeda, J.M., Rupprecht, R., Baghai, T.C. Neurobiology of depression: A neurodevelopmental approach. World J Biol Psychiatry. 2017 Mar 3:1-11.
  • Baghai, T.C. Zirngibl, C., Heckel, B., Sarubin, N., Rupprecht R. 2014 Individualized Pharmacological Treatment of Depressive Disorders State of the Art and Recent Developments, J Depress Anxiety 3 (2): 1-13.
  • Baghai, T.C., Blier, P., Baldwin, D.S., Bauer, M., Goodwin, G., Fountoulakis, K.N., Kasper, S., Leonard, B.E., Malt, U.F., Stein, D., Versiani, M., Möller, H.J. 2012 Executive summary of the report by the World Psychiatric Association section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 262(1):13-22.
  • Baghai, T.C., Varallo-Bedarida, G., Born, C., Häfner, Schüle, C., S., Eser, D., Zill, P., Rupprecht, R., Bondy, B., von Schacky, C. 2011 Major depression is associated with cardiovascular risk factors and low Omega-3 Index. Journal of Clinical Psychiatry 72 (9), 1242-1247.
  • Rupprecht, R., Papadopoulos, V., Rammes, G., Baghai, T.C., Fan, J., Akula, N., Groyer, G., Adams, D., Schumacher, M. 2010 Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nature Reviews Drug Discovery Vol. 9, 971-988.
  • Rupprecht, R., Rammes, G., Eser, D., Baghai, T.C., Schüle, C., Nothdurfter, C., Troxler, T., Gentsch, C., Kalkman, H.O., Chaperon, F., Uzunov, V., McAllister, K.H., Bertaina-Anglade, V., Drieu La Rochelle, C., Tuerck, D., Floesser, A., Kiese, B., Schumacher, M., Landgraf, R., Holsboer, F., Kucher, K. 2009 Translocator Protein (18 kDa) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects. Science 24, 490-493.
  • Sartorius, N., Baghai, T.C., Barrett, B., Baldwin, D.S., Brand, U., Fleischhacker, W., Goodwin, G., Grunze, H., Knapp, M., Leonard, B.E., Lieberman, J., Nakane, Y., Pinder, R.M., Schatzberg, A.F., Švestka, J. 2007 Antidepressant medications and other treatments of depressive disorders – A CINP task force report based on a review of evidence. The International Journal of Neuropsychopharmacology 10(1) 1-210
  • Baghai, T.C., Binder, E.B., Schüle, C., Salyakina, D., Zwanzger, P., Lucae, S. Eser, D., Haberger, C., Zill, P., Ising, M., Deiml, T., Uhr, M., Illig, T., Wichmann, H.E., Modell, S., Holsboer, F., Müller-Myhsok, B., Möller, H.J., Rupprecht, R., Bondy, B. 2006 Polymorphisms in the Angiotensin Converting Enzyme (ACE) Gene are associated with Unipolar Depression, ACE Activity and Hypercortisolism. Molecular Psychiatry Vol. 11, Nr. 11, 1003-1015.